Question 1

What specific tests will be done to check for circulating tumor cells?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

Question 2

How will the results of this study affect my treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the risks and benefits of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for tests or procedures?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if circulating tumor cells are found in my tests?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer clinical trial (NCT02732171). Contact the study team or your healthcare provider for specific answers.

What this study is about